Outcomes-based pricing doesn't cut costs of PCSK9 inhibitors
(HealthDay)—Outcomes-based pricing does not reduce the costs of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine.
Apr 3, 2018
0
3